NSE : DRREDDY BSE : 500124 ISIN CODE : INE089A01023 Industry : Pharmaceuticals & Drugs House : Dr. Reddy’s


Related News: 

Dr Reddy’s Laboratories Q3 net profit up 3,648% at Rs 707 crore

Dr. Reddy’s profit fell 28 percent; 9 percent growth in Annual revenue

Dr Reddy’s Laboratories shares falls 3%, hits 52-week low

Dr. Reddy’s announces DCGI approval to the single-shot Sputnik Light vaccine in India

Dr Reddy’s to manufacture baricitinib for Covid -19 treatment in India

Remediesivir: Remediesivir preparation at Dr. Reddy’s Labs

Company Overview: 

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the research, development, and commercialization of differentiated formulations for dermatology and neurology therapeutic areas. The Others segment engages in developing therapies in the fields of oncology and inflammation. As of March 31, 2021, it had three late stage projects at various stages of development. Its therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy’s Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Industry: Drug ManufacturersSpecialty & Generic
Sector: Healthcare
Phone: 91 40 4900 2900


Chairman K Satish Reddy
Managing Director GV Prasad
Company Secretary Sandeep Poddar
Non Executive Independent Director Allan Oberman
Bruce L A Carter
Kalpana Morparia
Leo Puri
Sridar Iyengar
Prasad R Menon
Shikha Sharma